Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

192
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
192
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

343
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
343
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

182
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
182
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

218
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
218
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

188
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
188
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

506
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
506

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Risk factors for lethal outcomes in elderly and senile patients with acute coronary syndrome: An analysis of a large vascular center registry.]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

Chronobiotics: classifications of existing circadian clock modulators, future perspectives.

Biomeditsinskaia khimiia·2024
Same author

[Novel integrative multi-omics strategies of human's biological age computation.]

Advances in gerontology = Uspekhi gerontologii·2024
Same author

[Artificial intelligence in pathological anatomy].

Arkhiv patologii·2024
Same author

[The Antioxidant and Geroprotective Properties of an Extract of Mountain Ash (Sorbus aucuparia L.) Fruits].

Molekuliarnaia biologiia·2023
Same author

[Drosophila melanogaster Lifespan Is Regulated by nejire Gene Expression in Peripheral Tissues and Nervous System].

Molekuliarnaia biologiia·2023

Related Experiment Video

Updated: Jan 12, 2026

Author Spotlight: In Vitro Investigations of Circadian Rhythms in Multicellular Systems
05:44

Author Spotlight: In Vitro Investigations of Circadian Rhythms in Multicellular Systems

Published on: February 16, 2024

1.7K

[Chronobiotics as potential geroprotectors.]

I A Solovev1, D A Golubev1

  • 1Pitirim Sorokin Syktyvkar State University, Medical Institute, 55 Oktyabrsky pr., Syktyvkar 167000, Russian Federation,

Advances in Gerontology = Uspekhi Gerontologii
|October 31, 2025
PubMed
Summary

Chronobiotics show promise for healthy aging by targeting circadian rhythms linked to age-related diseases. Further research is needed to overcome clinical challenges for effective geroprotection strategies.

Keywords:
agingchronobioticscircadian rhythmsgeroprotectorsmelatoninresveratrol

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

310

Related Experiment Videos

Last Updated: Jan 12, 2026

Author Spotlight: In Vitro Investigations of Circadian Rhythms in Multicellular Systems
05:44

Author Spotlight: In Vitro Investigations of Circadian Rhythms in Multicellular Systems

Published on: February 16, 2024

1.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

310

Area of Science:

  • Chronobiology
  • Gerontology
  • Pharmacology

Background:

  • Aging is associated with disrupted circadian regulation.
  • Circadian dysfunction contributes to neurodegenerative and metabolic disorders.
  • Chronobiotics modulate biological rhythms.

Purpose of the Study:

  • To analyze the impact of chronobiotics on aging processes.
  • To evaluate chronobiotics as potential geroprotectors.
  • To identify challenges and future directions for chronobiotic use in healthy aging.

Main Methods:

  • Review of existing scientific literature on chronobiotics and aging.
  • Analysis of key mechanisms in circadian regulation and age-related diseases.
  • Assessment of melatonin, resveratrol, and analogs as geroprotectors.

Main Results:

  • Chronobiotics, including melatonin and resveratrol, show potential for geroprotection.
  • Circadian rhythm mechanisms are linked to aging and related diseases.
  • Clinical implementation faces challenges like chronotype variability and lack of standardization.

Conclusions:

  • Chronobiotics represent a promising avenue for healthy aging interventions.
  • Addressing individual factors and standardizing protocols are crucial for clinical success.
  • Further research should focus on optimizing chronobiotic application for geroprotection.